Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
- Study type
- Clinical guideline
- Study name
- ESMO febrile neutropenia 2016
- Design
- Clinical Practice Guideline from the ESMO Guidelines Committee
- Source
- Annals of Oncology · 2016
In plain words
This document is a clinical guideline from the European Society for Medical Oncology (ESMO) on the management of febrile neutropenia. This condition means fever together with a low number of neutrophils (a type of white blood cell). Doctors use this guideline to make treatment decisions. Only your treating doctor can decide the exact recommendations for your situation.
Study population
The PubMed record has no abstract and does not state the target population. Details are in the full text of the guideline.
Endpoints
This document is a clinical guideline and has no endpoint. Details are in the full text of the guideline.
Safety and side effects
The PubMed record contains no information on adverse effects. Details are in the full text of the guideline.
Clinical significance and place in guidelines
The PubMed record contains only bibliographic information and gives no abstract or recommendations. The clinical impact and recommendations of the guideline must therefore be extracted from its full text, and whether the guideline is still current should be checked before use.
Limitations
This card is based only on the PubMed record, which has no abstract. The recommendations and levels of evidence should be completed from the full text of the guideline and confirmed by an oncology specialist. This guideline was published in 2016, and whether it is still current should be checked.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.